Indian Economy News

Pharma exports surpass US$ 31 billion in FY26 despite global headwinds

India’s pharmaceutical exports demonstrated resilience in FY26, surpassing Rs. 2.86 lakh crore (US$ 31 billion) despite challenging global conditions such as pricing pressures, regulatory hurdles and geopolitical uncertainties. The sustained growth reflects India’s strong position as a global supplier of affordable medicines, supported by its robust manufacturing base and diversified export markets. Key export segments include generic formulations, bulk drugs, vaccines and biosimilars, with major markets such as the US, Europe, Africa and emerging economies continuing to drive demand. India’s competitive advantage in cost-efficient production and regulatory compliance has enabled the sector to maintain steady export performance. The growth in exports has been supported by increasing global demand for high-quality generics, expansion into complex therapies and the strengthening of domestic pharmaceutical infrastructure. Government initiatives such as the Production Linked Incentive (PLI) scheme for pharmaceuticals and bulk drugs have enhanced domestic manufacturing capabilities and reduced import dependence. Additionally, Indian companies are focusing on research and development, regulatory approvals and diversification of product portfolios to tap into high-value markets.

The sector is also witnessing increased investments in biotechnology, biosimilars and speciality drugs, further strengthening its global competitiveness. Going forward, India’s pharmaceutical industry is expected to maintain its growth trajectory, driven by innovation, regulatory alignment and expanding global healthcare demand. Strategic focus on emerging markets, value-added products, and supply chain resilience will further enhance export potential. Overall, the strong export performance in FY26 underscores India’s role as a key player in the global pharmaceutical landscape and its continued contribution to global healthcare access.

Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.